Cite
Systemic Inflammatory Response Syndrome in End-Stage Heart Failure Patients Following Continuous-Flow Left Ventricular Assist Device Implantation: Differences in Plasma Redox Status and Leukocyte Activation.
MLA
Mondal, Nandan K., et al. “Systemic Inflammatory Response Syndrome in End-Stage Heart Failure Patients Following Continuous-Flow Left Ventricular Assist Device Implantation: Differences in Plasma Redox Status and Leukocyte Activation.” Artificial Organs, vol. 40, no. 5, May 2016, pp. 434–43. EBSCOhost, https://doi.org/10.1111/aor.12580.
APA
Mondal, N. K., Sorensen, E. N., Pham, S. M., Koenig, S. C., Griffith, B. P., Slaughter, M. S., & Wu, Z. J. (2016). Systemic Inflammatory Response Syndrome in End-Stage Heart Failure Patients Following Continuous-Flow Left Ventricular Assist Device Implantation: Differences in Plasma Redox Status and Leukocyte Activation. Artificial Organs, 40(5), 434–443. https://doi.org/10.1111/aor.12580
Chicago
Mondal, Nandan K., Erik N. Sorensen, Si M. Pham, Steven C. Koenig, Bartley P. Griffith, Mark S. Slaughter, and Zhongjun J. Wu. 2016. “Systemic Inflammatory Response Syndrome in End-Stage Heart Failure Patients Following Continuous-Flow Left Ventricular Assist Device Implantation: Differences in Plasma Redox Status and Leukocyte Activation.” Artificial Organs 40 (5): 434–43. doi:10.1111/aor.12580.